Integrated Prognostic Score in Metastatic Castration-resistant Prostate Cancer Treated with Cabazitaxel - A CABASTY...

Area of Science:

• Oncology
• Prostate Cancer Research
• Clinical Trial Analysis

Background:

• Optimal treatment post-docetaxel and androgen receptor pathway inhibitors (ARPI) in metastatic castration-resistant prostate cancer (mCRPC) is unclear.
• A prognostic and predictive score is needed to guide therapy selection for mCRPC patients.

Purpose of the Study:

• To develop and validate the cabascore, a tool to predict outcomes for mCRPC patients treated with cabazitaxel.
• To aid in tailoring treatment strategies for mCRPC patients based on their prognostic profile.

Main Methods:

• Post hoc analysis of the CABASTY trial to derive the cabascore using multivariable Cox models for overall survival (OS).
• Stratification into favorable, intermediate, and poor prognostic groups using log-rank optimization.
• Validation using data from the phase 3 CARD and PROSELICA clinical trials.

Main Results:

• The cabascore incorporates performance status, metastatic sites, PSA, LDH, alkaline phosphatase, and hemoglobin.
• Median OS varied significantly across prognostic groups: 21.6 months (favorable), 12.5 months (intermediate), and 6.2 months (poor).
• Validation in PROSELICA and CARD confirmed cabascore's ability to stratify OS, with cabazitaxel showing improved OS over ARPI in the favorable group in the CARD trial.

Conclusions:

• The cabascore can assist in personalizing treatment decisions for mCRPC patients.
• Cabazitaxel may offer greater survival benefits for patients with a favorable prognosis compared to second-line ARPI therapy.